- Sumitomo Dainippon-Roivant Alliance ("Alliance") encompasses up to 11 biopharmaceutical Vants with more than 25 innovative clinical programs and multiple potential product launches from 2020 to 2022, and access to key elements of Roivant's proprietary technology platforms including DrugOme and Digital Innovation
- Sumitomo Dainippon Pharma to enter into contract agreements with Roivant Health technology Vants including Datavant and Alyvant
- Sumitomo Dainippon Pharma to take over 10% equity stake in Roivant
- Parties have entered into a non-binding memorandum of understanding ("Memorandum"); a definitive agreement expected by the end of October 2019
PR Newswire
TOKYO, OSAKA, Japan, LONDON, and BASEL, Switzerland, Sept. 5, 2019